The immune system plays a key role in the anti-tumor effect of trastuzumab, which occurs through the binding of the HER2 receptor by the fragment antigen binding (Fab) and Fc to the CD16 of NK cells (23). The gene discussed is FCGR3A; the disease is neoplasm.